New combo shows promise for Tough-to-Treat lung cancer
NCT ID NCT04147351
First seen May 02, 2026 · Last updated May 26, 2026 · Updated 6 times
Summary
This study tested a combination of four drugs (atezolizumab, bevacizumab, platinum chemotherapy, and pemetrexed) in 22 adults with advanced EGFR-mutant non-small cell lung cancer that had stopped responding to standard targeted therapy. The goal was to see how many patients' tumors shrank or disappeared. The approach aims to control the disease rather than cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IIIB~IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.